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Summary The effect of 10-6M tamoxifen on MCF-7 cells adapted to growth in 0.5% foetal calf serum has
been studied. The growth inhibitory effect of this tamoxifen concentration was abolished by simultaneous
addition of 10-8M oestradiol, indicating that tamoxifen may exert its effect via binding to the oestrogen
receptor. Flow cytometric cell cycle analysis of tamoxifen-treated cultures showed an increase in the pro-
portion of cells in the GI phase of the cell cycle. By exposing the cells to BUdR before flow cytometry the
growth fraction was determined and found to be dramatically decreased in tamoxifen-treated cultures. Cells
were not only arrested in the G, phase but also in the G2 phase of the cell cycle. A few colonies of MCF-7
cells were resistant to 10 days treatment with 106M tamoxifen.
The antioestrogen tamoxifen is widely used for
treatment of patients with breast cancer. In general,
patients with oestrogen receptor-positive tumours
have a response rate of 50%, whereas patients with
oestrogen receptor-negative tumours have a
response rate of only 10% (Mouridsen et al., 1978;
Rose et al., 1980). The effect of tamoxifen has
therefore been attributed to the presence of
oestrogen receptors.
It is believed that tamoxifen acts by interfering
with oestrogen receptor function at some level,
though a specific antioestrogen receptor has been
reported to exist in human breast cancer
(Sutherland & Murphy, 1980), human endometrium
(Sutherland et al., 1980), rat liver (Sutherland et al.,
1980; Winneker & Clark, 1983), rat uterus
(Winneker & Clark, 1983) and in human breast
cancer cell lines (Miller & Katzenellenbogen, 1983).
The antioestrogen receptor content is unrelated to
the oestrogen receptor content, and the role of the
antioestrogen receptor is still unknown. Miller &
Katzenellenbogen (1983) suggest that the inter-
action with the oestrogen receptor and not with the
antioestrogen receptor is most likely to be the
mechanism underlying the growth inhibitory effects
of antioestrogens. Rochefort et al. (1981) have
found that tamoxifen binds specifically to the
oestrogen receptor and not to other saturable
proteins. However, they measured receptors in the
cytosol and the nuclear KC1 extract whereas the
specific antioestrogen binding sites are said to be
located in the microsome preparation. They
conclude that tamoxifen blocks the growth of
human breast cancer by antagonizing the
stimulatory effect of oestrogens. This mechanism
cannot explain the growth inhibitory effect of
tamoxifen on our MCF-7 cells since these cells do
not respond to oestradiol (Briand & Lykkesfeldt,
1984). Depending on the concentration, tamoxifen
inhibition was either oestrogen reversible or
oestrogen irreversible. In the present work we have
used 10-6M tamoxifen, which is the highest
concentration of tamoxifen, the effect of which can
be abolished by oestradiol.
Sutherland and Taylor (1981) and Greene et al.
(1981) have studied the effect of cytotoxic concen-
trations of tamoxifen on the cell cycle kinetics of
MCF-7 and found an accumulation of cells in the
G, phase. Two recent reports describe the use of
lower concentrations of tamoxifen, where the effect
can be reversed by oestradiol (Sutherland et al.,
1983; Osborne et al., 1983). The tamoxifen
treatment results in an accumulation of cells in the
G1 phase of the cell cycle and Sutherland et al.
(1983) conclude that tamoxifen is a cell cycle phase-
specific growth inhibitory agent. In this study we
have investigated whether the accumulation of cells
with a G1 amount of DNA can be ascribed to non
cycling cells, and we have also tested whether
tamoxifen blocks cells in phases of the cell cycle
other than the G, phase.
Materials and methods
Cell culture
MCF-7 cells were kindly supplied from the Human
Cell Culture Bank, Mason Research Institute,
Rockville, Md., USA. They were propagated in
plastic T flasks (Nunc, Denmark) in Dulbecco's
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MEM+Ham's F12 (1:1) supplemented with
glutamine 2mM, insulin 6ngml l and 0.5% heat
inactivated foetal bovine serum. The cells had been
adapted to growth at this serum concentration since
passage 247 (Briand and Lykkesfeldt, 1984); cells
from passage 336 were used in this study. In the
experiments growth medium was replaced by the
test medium one day after seeding: this consisted of
growth medium supplemented with hydrocortisone
(10-8M) and prolactin (1 Mgml-1). The flasks were
divided into two groups. A tamoxifen group, which
received 10-6M tamoxifen dissolved in ethanol
(final conc. 0.1%), and a control group to which
ethanol was added at a final concentration of 0.1%.
The medium was renewed daily during the
experiment.
Growth curves
Three cultures were trypsinized and the cells
counted in a Burker-Turck chamber one day after
seeding. These counts represent the cell number at
day 0. Three cultures from each group were
counted on designated days of the experiment.
Preparation ofnucleiforflow cytometry
The cells were removed from the flasks with 1 mM
EDTA in a buffer (137mM NaCl, 2.7mM KCI,
8.1mM Na2HPO4, 1.5mM KH2PO4, pH 7.4) and
washed twice with this buffer. They were lysed with
1% Triton X-100 in the buffer supplemented with
2mM EGTA, 1.5mM MgCl2, pH 7.2 and citric
acid added to a final concentration of 2% (Miller,
1979). Nuclei were pelleted by centrifugation at
800g for 10min, resuspended in the buffer with
2mM EGTA, 1.5mM MgCl2 and 0.2% Triton X-
100, pH 7.2 and stained with propidium iodide or
mithramycin.
Flow cytometry
For conventional flow cytometric cell cycle analysis
the samples were stained by addition of propidium
iodide (50pgmlF 1, Sigma) and RNase (0.1 mgml-1,
Sigma type lA) for at least 30min. For
determination of the growth fraction after
incubation with BUdR the samples were stained by
addition of mithramycin (20ligml-1, Mithracin ,
Pfizer) and MgCl2 (25mM) (Swartzendruber, 1977).
As internal DNA references stained chicken and
trout erythrocyte nuclei were added to each sample.
Batches of chicken and trout blood cells were kept
frozen in buffer (250mM sucrose, 40mM sodium
citrate, 5% dimethylsulfoxide, pH 7.6). Aliquots
were thawed and lysis buffer added (IOmM Tris,
1 mM EGTA, 1% Nonidet P 40) prior to staining
(Vindel0v et al., 1982c). All stained samples were
filtered through 304m nylon mesh before flow
cytometry. The flow cytometer used was a Becton
Dickinson FACS IV Cell Sorter with a Spectra
Physics 5 W argon laser nm, 488mW for propidium
iodide; 457nm, 100mW for mithramycin).
Determination ofgrowthfraction
5-Bromodeoxyuridine, BUdR (final concentration
0.02mM) was added to two T-25 flasks in each
group at day 4. The cells were harvested 48h later
and nuclei prepared for flow cytometry. The
growth of the cultures is unaffected by the presence
of BUdR for at least two generation times. Cells
which have not incorporated BUdR after
administration for a generation time, may either be
Go cells or cells with an unusually long cell cycle
time. In this experiment cells were harvested after a
period of approximately two generation times in the
control culture. Cells with a G1 amount of normal
DNA are defined as Go cells but may include cells
with a G1 transit time longer than two generation
times. The proportion of Go cells may be
underestimated, because it is calculated as the
proportion of cells with a G1 amount of normal
DNA out of the total number of cells which
increases by cell division. Underestimation of the
Go fraction caused by detachment of non cycling
cells can be excluded since flow cytometry has
shown that the non cycling cells are still present in
the cultures after 96h in BUdR medium.
Statistics
The phase fractions of the DNA histograms were
estimated by fitting the observed distributions of
fluorescence (deconvolution) by maximum
likelihood using a statistical model described
earlier (Christensen et al., 1978; Vindelbv et al.,
1982b). The proportion of non cycling cells (Go) in
the flow cytometric histograms of DNA from
BUdR treated cultures was estimated in a similar
manner using mixtures of Gaussians to fit the
additional peaks (Vindeliv et al., 1982a).
Results
The growth curves of control and tamoxifen treated
cultures are shown in Figure 1. The control cultures
grow exponentially for the first 6 days with a
doubling time of 20h. Thereafter the doubling time
increases gradually. The cell number increases in
the tamoxifen treated cultures for the first 5 days,
but with an increased doubling time compared to
the control culture. After day 6 the cells detach
from the flasks and at day 7 a great variation in the
cell number is seen in the different flasks. By day
10 only a few flasks contained colonies of growing
cells.TAMOXIFEN - CELL CYCLE KINETICS OF MCF-7 719
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Figure 1 Growth curves for control cultures of
MCF-7 cells (0) and cultures treated with 10-6M
tamoxifen (@). The lines are drawn between median
cell number of 3 flasks. At day 10 two flasks from the
tamoxifen treated cultures were empty and few cells
were present in the third flask.
At days 3, 4, 5, 6, 7 and 10, cells were harvested
from control and tamoxifen treated cultures and
nuclei prepared and stained for flow cytometric
analysis as described in Materials and methods.
Figure 2 shows the DNA distribution in control
and tamoxifen treated cultures at day 4. From such
histograms the distribution of cells in the different
phases of the cell cycle was calculated as described
above. The number of cells analyzed in each sample
was > 10,000, apart from the tamoxifen culture at
day 6, where only 5200 cells were analyzed. Even
with the low number of cells, the standard error
due to deconvolution of the DNA histograms has
been shown to be <2% of the total number of cells
(Vindeliv et al., 1982b). The results of these
analyses are shown in Figures 3A, 3B and 3C. The
effect of tamoxifen on the proportion of cells with
a G1 amount of DNA is shown in Figure 3A and it










Figure 2 DNA histograms from (a) control culture of
MCF-7 cells and (b) tamoxifen (10-6M) treated
culture at day 4. The DNA was stained with
propidium iodide and measured by flow cytotometry
with chicken and trout erythrocyte nuclei as internal
references.
a greater proportion of the cells in the tamoxifen
treated cultures had a G1 amount of DNA. This
difference in the proportion of cells with a G,
amount of DNA was evident for the first 7 days
but at day 10 no difference was observed. In Figure
3B the proportion of cells in the S phase is shown
as a function of the treatment time and here a





















SO720 A.E. LYKKESFELDT et al.
At day 10 no significant difference was observed
between the proportion of cells in G2+M in
tamoxifen treated and control cultures.
The proportion of cells participating in cell cycle
events was measured by the BUdR-technique.
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Figure 3 Effect of 10-6M tamoxifen on the cell cycle
kinetic parameters of MCF-7 cells. The proportion of
cells in the different phases of the cell cycle was
calculated from DNA histograms as presented in
Figure 2. Control cultures (0), tamoxifen cultures
(0).
treated for 3-7 days with tamoxifen. At day 10 no
difference was observed. Figure 3C shows the
proportion of cells in G2 +M and after 4-7 days
treatment fewer cells in the tamoxifen treated
cultures were in G2+M than in the control culture.
Channel
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Figure 4 Flow cytometric mithramycin fluorescence
histograms from (a) control and (b) tamoxifen cultures
of MCF-7 cells. The cells were harvested after
treatment from days 4-6 (48h) with 0.02mM BUdR.
Go refers to the position for G1 amount of normal
DNA, G1* to G1 amount of DNA with BUdR in one
strand, G1** to G1 amount of DNA with BUdR in
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a control culture and a tamoxifen treated culture
exposed 48h to BUdR in the period from days 4-6
of the experiment. During this period the median
cell number in the control cultures increased from
3.2 x 105 to 12.0 x 105. The peak to the left in the
histogram, representing cells with a G1 amount of
DNA without BUdR, is indicated in the figure as
Go and amounts to 2% of the total cell number.
The next peak represents cells with a G1 amount of
DNA containing BUdR in one strand. In the
tamoxifen cultures the median cell number during
the time of exposure to BUdR increased from
3.6 x 104 to 8.5 x 104. The peak representing cells
with a G1 amount of DNA without incorporated
BUdR is indicated in the figure as Go and
represents 43% of the total cell number. A peak
with a G2 amount of DNA without BUdR is
present in the histogram of tamoxifen treated cells,
but not in the control histogram.
Discussion
We have demonstrated that 10-6M tamoxifen
inhibits growth in vitro of the human breast cancer
cell line, MCF-7 by reducing the growth fraction.
Furthermore, we have shown that cells were
arrested not only in the G1 phase of the cell cycle
as previously described (Osborne et al., 1983;
Sutherland et al., 1983), but also in the G2 phase.
The inhibitory effect of 10-6M tamoxifen can be
abolished by simultaneous addition of 10-8M
oestradiol and no effects on cell cycle kinetics are
observed under these conditions. Lower concen-
trations of tamoxifen also inhibit growth, though to
a smaller extent. In agreement with others (Horwitz
& McGuire, 1978) we have also found that
tamoxifen binds to the oestrogen receptor and the
oestrogen receptor-tamoxifen complex translocates
to the nucleus. The oestrogen receptor-negative cell
line, HBL-100 originating from cells in normal
human milk is completely insensitive to tamoxifen
concentrations up to 2 x10-6M (Briand &
Lykkesfeldt, 1984) indicating that the oestrogen
reversible effect of tamoxifen in MCF-7 cells is
mediated via the oestrogen receptor mechanism.
The inhibition of cell proliferation was mainly
due to an.accumulation of cells with a G1 amount
of DNA. This accumulation of cells in the G1
phase of the cell cycle occurs already after 3 days
of treatment with tamoxifen. Prolonged treatment
leads to further increase in the G1 population.
However, the DNA distribution after 10 days of
treatment is very similar to the DNA distribution in
the control culture. This reflects the very dramatic
changes which occur from days 7-10, viz that the
majority of the cells in the cultures have died and
disappeared and only a few culture flasks contained
colonies of live cells. The DNA measurements were
done on cells from these selected flasks with viable
cells and their DNA distribution indicates that they
may be proliferating. This is supported by our
observation of the presence of mitoses in the viable
colonies. We conclude that the majority of the
MCF-7 cells are tamoxifen sensitive and the cell
kinetic observations from days 3-7 reflect the effect
of tamoxifen on sensitive cells. A minor fraction of
the MCF-7 cells are apparently tamoxifen resistant
since they still proliferate after 10 days of
treatment. We have now treated MCF-7 cultures
with 10-6M tamoxifen for up to one month and
isolated growing colonies from such cultures. These
MCF-7 cell sublines are now under investigation
and they can be subcultured several times in the
presence of 10-6M tamoxifen, indicating that they
are tamoxifen resistant. Usually, MCF-7 cells
cannot be subcultured in tamoxifen medium after
one week of treatment with 10-6M tamoxifen.
Resistance to tamoxifen treatment has been shown
in the cell kinetic work of Osborne et al. (1983),
and two human breast cancer cell sublines resistant
to tamoxifen have been isolated and characterized
(Nawata et al., 1981, Horwitz et al., 1982).
Sutherland et al. (1983) describe tamoxifen as a
cell cycle phase specific growth inhibitory agent,
which blocks cells in the GO/Gl phase of the cell
cycle, and Osborne et al. (1983) suggest that
tamoxifen inhibits cell proliferation by invoking a
transition delay or block in the early-to-mid-G1
phase of the cell cycle. By the BUdR-mithramycin
method applied in this study it is possible to
identify the cells which do not participate in cell
cycle events. We find that tamoxifen treatment
reduces the growth fraction considerably and both
cells with a G1 amount of DNA and cells with a
G2 amount of DNA are growth arrested. The
BUdR-mithramycin technique does not allow a
determination of cells arrested in the S phase.
This is the first study to demonstrate that both
cells with a G1 amount of DNA and a G2 amount
of DNA are growth arrested after tamoxifen
treatment. By conventional flow cytometry an
accumulation of cells in one compartment may
indicate a single block in the cell cycle. However,
identification of more than one block in the cell
cycle is more difficult, since an accumulation in one
compartment may be hidden by a decreased entry
of cells into the compartment due to a block in
another compartment. The BUdR-mithramycin
technique is therefore superior to conventional flow
cytometry because both non cycling cells with a G1
amount of DNA and a G2 amount of DNA can be
identified.
If the MCF-7 model is representative of human
breast cancer, the results of these experiments may
give valuable information to clinicians for the722 A.E. LYKKESFELDT et al.
treatment of this disease. Tamoxifen inhibits
growth by reducing the growth fraction and non
cycling cells may survive in the tumour for a rather
long period of time before they die, indicating the
need for long term treatment with tamoxifen. The
finding of tamoxifen resistant cells suggests that
combined endocrine and cytotoxic treatment may
give better overall survival than tamoxifen alone.
Knowledge about the effect of tamoxifen on cell
cycle kinetic parameters may be useful for the
choice and scheduling of combined treatment
regimes.
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